Scientist / Associate Scientist, Immunology
Fate Therapeutics is seeking a highly motivated and talented molecular immunologist to support our research programs. Knowledge and experience in a wide-range of immunology, immuno-oncology, transcriptome sequencing, and gene-editing strategies is required. Experience and expertise in genome-wide CRISPR screening and/or single-cell characterization and corresponding data analysis techniques is highly desired. This position will be a key member of our immuno-oncology team and will assist in performing and analyzing studies involving in vitro, ex vivo, an in vivo testing of Fate Therapeutics’ novel cellular therapy products. This is a full-time, bench-level position and is located at the Company’s corporate headquarters in San Diego, California.
- Gene editing of human immune cells including the application of the most commonly used gene editing strategies (e.g., Lenti, CRISPR)
- Genetic screening of human immune cells (e.g. CRISPR screens)
- Creation of Next Generation Sequencing (NGS) libraries from isolated genomic DNA and/or total RNA
- Development and execution of methods for preparing tissue and tumor samples for in-depth single cell analysis (e.g., NGS, FACs)
- Development and execution of novel single cell molecular biology schemes, including combined Protein/RNA-seq (e.g., CITE-seq, REAP-seq)
- Application of traditional immunological, cellular and molecular biology techniques to support Fate’s programs in the areas of tumor immunology and cellular based immunotherapies
- Work closely with cross-functional teams to interpret NGS data from single cell and tissue samples to guide Fate’s product development pipeline
- Presentation of data to immunology groups and larger program-specific teams
- Ph.D. degree in Immunology or Molecular Biology or other related fields with at least 2 years of post-doctoral experience; applicants with MS or BS degree and extensive (> 8 years) experience may also be considered for the position
- Expertise in cell-based screening, particularly genetic screens utilizing genome-wide CRISPR approaches
- Experience in single-cell genomics or functional genomics is a plus
- Proven ability to develop advanced cell, tissue, and tumor analysis methods highly desired
- In-depth experience in developing and executing immunological assays utilizing primary human T- and NK-cells
- Proven ability to coordinate with multiple researchers for scheduling and execution of complex experiments
- Excellent communication and organization skills are a must
- Positive outlook and a team-oriented attitude
Working Conditions and Physical Requirements
- Will require working with cells and cell lines of human and/or animal origin
- Occasional weekend and/or evening hours required
- 100% on site work at corporate headquarters in San Diego, CA
The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.
For consideration send cover letter and curriculum vitae to: firstname.lastname@example.org and reference job 189JR.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell therapies using its proprietary induced pluripotent stem cell (iPSC) product platform. This platform uniquely enables the single-cell selection of a precisely engineered iPSC clone and the subsequent creation and maintenance of a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for consistently and repeatedly manufacturing homogeneous cell products in quantities that support the treatment of many thousands of patients in an off-the-shelf manner. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.